As of 2024-12-15, the Relative Valuation of Hansa Biopharma AB (HNSA.ST) is (188.76) SEK. This relative valuation is based on P/E multiples. With the latest stock price at 30.52 SEK, the upside of Hansa Biopharma AB based on Relative Valuation is -718.5%.
The range of the Relative Valuation is (195.04) - (196.01) SEK.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 16.2x - 21.5x | 18.8x |
| Forward P/E multiples | 20.2x - 20.3x | 20.2x |
| Fair Price | (195.04) - (196.01) | (188.76) |
| Upside | -739.1% - -742.2% | -718.5% |
| Date | P/E |
| 2024-12-11 | -3.16 |
| 2024-12-10 | -3.14 |
| 2024-12-09 | -3.15 |
| 2024-12-06 | -3.25 |
| 2024-12-05 | -3.21 |
| 2024-12-04 | -3.26 |
| 2024-12-03 | -3.27 |
| 2024-12-02 | -3.26 |
| 2024-11-29 | -3.37 |
| 2024-11-28 | -3.37 |
| 2024-11-27 | -3.21 |
| 2024-11-26 | -3.21 |
| 2024-11-25 | -3.26 |
| 2024-11-22 | -3.18 |
| 2024-11-21 | -3.09 |
| 2024-11-20 | -3.17 |
| 2024-11-19 | -3.10 |
| 2024-11-18 | -3.09 |
| 2024-11-15 | -3.28 |
| 2024-11-14 | -3.42 |
| 2024-11-13 | -3.37 |
| 2024-11-12 | -3.13 |
| 2024-11-11 | -3.26 |
| 2024-11-08 | -3.41 |
| 2024-11-07 | -3.45 |
| 2024-11-06 | -3.35 |
| 2024-11-05 | -3.48 |
| 2024-11-04 | -3.63 |
| 2024-11-01 | -3.80 |
| 2024-10-31 | -3.76 |
| 2024-10-30 | -3.88 |
| 2024-10-29 | -3.92 |
| 2024-10-28 | -3.99 |
| 2024-10-25 | -4.01 |
| 2024-10-24 | -4.10 |
| 2024-10-23 | -4.12 |
| 2024-10-22 | -4.12 |
| 2024-10-21 | -4.20 |
| 2024-10-18 | -4.19 |
| 2024-10-17 | -4.28 |
| 2024-10-16 | -4.16 |
| 2024-10-15 | -4.23 |
| 2024-10-14 | -4.24 |
| 2024-10-11 | -4.31 |
| 2024-10-10 | -4.25 |
| 2024-10-09 | -4.54 |
| 2024-10-08 | -4.53 |
| 2024-10-07 | -4.76 |
| 2024-10-04 | -4.15 |
| 2024-10-03 | -4.04 |